−44.62MXN
−2.40 BMXN
526.35 MMXN
50.81 M
About MARINUS PHARMACEUTICALS INC
Sector
CEO
Scott N. Braunstein
Headquarters
Radnor
Website
Employees (FY)
165
Founded
2003
ISIN
US56854Q2003
FIGI
BBG00JCHDDZ6
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
MRNS Breakout! don't sleep on this one! 100% upsideLook at the flat top breakout triangle forming on the MRNS chart! Classic structure and even better yet; Price target consensus of $30 among wall street analysts!
Marinus Pharmaceuticals, Inc. Rallying Pre-MarketMarinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, ca
Marinus Pharmaceuticals, Bullish breakout Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, ca
Plausible acquisition targetPotential near-term catalysts:
- breakthrough therapy designation in RSE
- end-of-PhII meetings for PPD and RSE
- partnership or acquisition
Thesis summary:
Drug showed 100% seizure control at 24h in PhII trial in patients with drug-resistant, life-threatening seizures (RSE)
Intravenous formulatio
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wa
$MRNS On watchlist for a breakout on impending news possibly .The price action has been quite positive in the stock of NASDAQ:MRNS in 2019 gaining almost 65% from the oversold lows in December. Like all Pharmaceutical companies, trails results can move the stock incredibly fast, speculation and rumor has it that the stock is due for a considerable breakout W
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MRNS is 124.00 MXN — it has decreased by 2.36% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange MARINUS PHARMACEUTICALS INC stocks are traded under the ticker MRNS.
MARINUS PHARMACEUTICALS INC is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
MRNS stock is 2.42% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is MARINUS PHARMACEUTICALS INC there?
One year price forecast for MARINUS PHARMACEUTICALS INC has a max estimate of 461.06 MXN and a min estimate of 34.15 MXN.
MRNS earnings for the last quarter are −10.63 MXN per share, whereas the estimation was −11.52 MXN resulting in a 7.70% surprise. The estimated earnings for the next quarter are −10.59 MXN per share. See more details about MARINUS PHARMACEUTICALS INC earnings.
MARINUS PHARMACEUTICALS INC revenue for the last quarter amounts to 127.91 M MXN despite the estimated figure of 110.13 M MXN. In the next quarter revenue is expected to reach 135.97 M MXN.
Yes, you can track MARINUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MRNS stock has fallen by 8.82% compared to the previous week, the month change is a 8.82% fall, over the last year MARINUS PHARMACEUTICALS INC has showed a 49.40% increase.
MRNS net income for the last quarter is −709.45 M MXN, while the quarter before that showed −574.73 M MXN of net income which accounts for −23.44% change. Track more MARINUS PHARMACEUTICALS INC financial stats to get the full picture.
Today MARINUS PHARMACEUTICALS INC has the market capitalization of 1.32 B, it has decreased by 8.83% over the last week.
No, MRNS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MRNS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MARINUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 165.00 employees. See our rating of the largest employees — is MARINUS PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MARINUS PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MARINUS PHARMACEUTICALS INC stock shows the sell signal. See more of MARINUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MARINUS PHARMACEUTICALS INC future price: according to them, MRNS price has a max estimate of 461.06 MXN and a min estimate of 34.15 MXN. Read a more detailed MARINUS PHARMACEUTICALS INC forecast: see what analysts think of MARINUS PHARMACEUTICALS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MARINUS PHARMACEUTICALS INC EBITDA is −2.22 B MXN, and current EBITDA margin is −422.52%. See more stats in MARINUS PHARMACEUTICALS INC financial statements.